Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 295

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program

Aurora, Sheena K., Winner, Paul, Freeman, Marshall C., Spierings, Egilius L., Heiring, Jessica O., DeGryse, Ronald E., VanDenburgh, Amanda M., Nolan, Marissa E., Turkel, Catherine C.·2011·Headache: The Journal of Head and Face Pain

Abstract

Objective.— To evaluate safety and efficacy of onabotulinumtoxinA (BOTOX ® ) as headache prophylaxis in adults with chronic migraine. Background.— Chronic migraine is a prevalent, disabling, and undertreated neurological disorder. OnabotulinumtoxinA is the only approved prophylactic therapy in this highly disabled patient population. Design and Methods.— Two phase III, 24‐week, double‐blind, parallel‐group, placebo‐controlled studies, followed by a 32‐week, open‐label, single‐treatment, onabotulinumtoxinA phase, were conducted (January 23, 2006 to August 11, 2008). Qualified subjects were randomized (1:1) to injections of onabotulinumtoxinA (155‐195 U) or placebo every 12 weeks for 5 cycles (double‐blind: 2, open‐label: 3). The pooled primary variable was mean change from baseline in frequency of headache days. Secondary variables included proportion of patients with severe Headache Impact Test‐6 score (≥60) and mean changes from baseline in frequencies of migraine days, moderate/severe headache days, and migraine episodes; cumulative hours of headache on headache days; and acute headache medication intakes. The primary time point was week 24. Assessments for the open‐label phase (all patients treated with onabotulinumtoxinA) compared double‐blind treatment groups (onabotulinumtoxinA/onabotulinumtoxinA vs placebo/onabotulinumtoxinA) and are summarized to give a descriptive view of consistent study results, with inferences regarding statistical significance only examined for week 56. Results.— A total of 1384 patients were randomized to onabotulinumtoxinA (n = 688) or placebo (n = 696) in the double‐blind phase; 607 (88.2%) onabotulinumtoxinA/onabotulinumtoxinA and 629 (90.4%) placebo/onabotulinumtoxinA patients continued into the open‐label phase. OnabotulinumtoxinA/onabotulinumtoxinA treatment statistically significantly reduced headache‐day frequency vs placebo/onabotulinumtoxinA in patients with chronic migraine at week 56 (−11.7 onabotulinumtoxinA/onabotulinumtoxinA, −10.8 placebo/onabotulinumtoxinA; P = .019). Statistically significant reductions also favored onabotulinumtoxinA/onabotulinumtoxinA for several secondary efficacy variables at week 56, including frequencies of migraine days (−11.2 onabotulinumtoxinA/onabotulinumtoxinA, −10.3 placebo/onabotulinumtoxinA; P = .018) and moderate/severe headache days (−10.7 onabotulinumtoxinA/onabotulinumtoxinA, −9.9 placebo/onabotulinumtoxinA; P = .027) and cumulative headache hours on headache days (−169.1 onabotulinumtoxinA/onabotulinumtoxinA, −145.7 placebo/onabotulinumtoxinA; P = .018). After the open‐label phase (all treated with onabotulinumtoxinA), statistically significant within‐group changes from baseline were observed for all efficacy variables. Most patients (72.6%) completed the open‐label phase; few discontinued because of adverse events. No new safety or tolerability issues emerged. Conclusions.— Repeated treatment with ≤5 cycles of onabotulinumtoxinA was effective, safe, and well tolerated in adults with chronic migraine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1526-4610.2011.01990.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 295

Metadata

Authors
Aurora, S. K., Winner, P., Freeman, M. C., Spierings, E. L., Heiring, J. O., DeGryse, R. E., VanDenburgh, A. M., Nolan, M. E., & Turkel, C. C.
Venue
Headache: The Journal of Head and Face Pain
Publisher
Wiley
Published
2011-08-29
Volume
51
Issue
9
Pages
1358-1373
ISSN
  • 0017-8748 (ISSN-L)
  • 1526-4610
OpenAlex
W1994481205
Cited by
295
References
3
FWCI
9.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program. https://app.cochat.ai/papers/10.1111/j.1526-4610.2011.01990.x
The paper
Aurora, S. K., Winner, P., Freeman, M. C., Spierings, E. L., Heiring, J. O., DeGryse, R. E., VanDenburgh, A. M., Nolan, M. E., & Turkel, C. C. (2011). OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2011.01990.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.